# Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

> **NCT03401060** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 24 (actual)

## Conditions studied

- Osteoporosis
- Systemic Mastocytosis

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03401060
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2024-03-11
- **Final completion:** 2024-03-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401060, "Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03401060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*